News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tercica, Inc. (TRCA) Announces Results from Increlex® IGFD Patient Registry and Other Increlex® Studies at the 90th Meeting of the Endocrine Society


6/16/2008 1:11:51 PM

BRISBANE, Calif.--(BUSINESS WIRE)--Tercica, Inc. (NASDAQ: TRCA) today announced the first results from the Increlex® Growth Forum Database (IGFD) Registry in two posters presented at the 90th annual meeting of the Endocrine Society in San Francisco. Increlex® (mecasermin (rDNA origin) injection) is currently approved in the United States for the treatment of severe Primary IGF-1 Deficiency.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES